Surrozen doses first DUET patient, expands Phase 2a to 150 patients in DME study
Surrozen reported the first patient dosed in its SZN-8141 Phase 1b/2a trial and a planned Phase 2a enrollment increase, alongside added capital extending cash runway into 2029.
Surrozen, Inc. (Nasdaq: SRZN) reported on November 9, 2026 that it dosed its first patient in the open-label Phase 1b single-ascending-dose portion of DUET, a Phase 1b/2a clinical study evaluating SZN-8141 in patients with diabetic macular edema (DME).1 The Phase 1b portion is designed to evaluate safety and tolerability, as well as pharmacokinetics, immunogenicity and exploratory measures of biological and clinical activity.1
The company said it plans to expand the randomized, double-masked Phase 2a portion of DUET from approximately 60 to 150 patients.1 The expanded Phase 2a is expected to evaluate two dose levels of SZN-8141 compared with Vabysmo® (faricimab-svoa) in patients with DME and include both treatment-naïve and treatment-experienced patients.1
On timing, Surrozen said topline data from the DUET Phase 1b are expected in the second half of 2027, with topline data from the DUET Phase 2a expected in 2028.1 The company also said it is planning to develop SZN-8141 in neovascular age-related macular degeneration and is evaluating development in other retinal vascular diseases.1
On financing, Surrozen said that in October 2026 it finished the remaining installment of its March 2025 private placement, bringing in about $95.1 million before fees, and separately raised about $29.8 million net through its at-the-market stock sale program, money it said would help fund the larger Phase 2a trial In October 2026, Surrozen closed the second and final tranche of its March 2025 private placement, generating approximately $95.1 million in gross proceeds before deducting placement agent fees and other offering expenses... In October 2026, Surrozen raised approximately $29.8 million in net proceeds through its at-the-market offering program, further strengthening its balance sheet and supporting the expansion of the DUET Phase 2a study.1
As of September 30, 2026, Surrozen held cash and cash equivalents of $100.4 million, compared to $102.0 million as of June 30, 2026.1 Including the post-quarter raises, pro forma cash and cash equivalents were approximately $220.3 million as of September 30, 2026.1 The company said this funding is expected to provide cash runway into 2029, including funding for completion of the expanded DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b clinical development of SZN-8143.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.